Lion Biotechnologies, Inc. (IOVA) Receives “Buy” Rating from Jefferies Group LLC

Jefferies Group LLC reaffirmed their buy rating on shares of Lion Biotechnologies, Inc. (NASDAQ:IOVA) in a research note issued to investors on Sunday.

A number of other equities analysts have also recently commented on IOVA. Chardan Capital reissued a buy rating on shares of Lion Biotechnologies in a research note on Thursday, September 7th. HC Wainwright reissued a buy rating and issued a $16.00 price objective on shares of Lion Biotechnologies in a research note on Wednesday, August 16th. FBR & Co reissued a buy rating and issued a $17.50 price objective on shares of Lion Biotechnologies in a research note on Wednesday, October 25th. Oppenheimer Holdings Inc. set a $13.00 price target on shares of Lion Biotechnologies and gave the stock a buy rating in a research note on Friday, August 18th. Finally, Zacks Investment Research raised shares of Lion Biotechnologies from a hold rating to a buy rating and set a $8.25 price target for the company in a research note on Tuesday, October 17th. Ten analysts have rated the stock with a buy rating, Lion Biotechnologies presently has a consensus rating of Buy and a consensus target price of $14.09.

Lion Biotechnologies (NASDAQ IOVA) traded up 4.79% during mid-day trading on Friday, reaching $7.65. 508,643 shares of the company’s stock traded hands. Lion Biotechnologies has a one year low of $4.45 and a one year high of $8.60. The firm’s 50-day moving average price is $7.53 and its 200 day moving average price is $6.48. The firm’s market cap is $547.18 million.

ILLEGAL ACTIVITY WARNING: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.com-unik.info/2017/10/30/lion-biotechnologies-inc-iova-receives-buy-rating-from-jefferies-group-llc.html.

A number of institutional investors have recently added to or reduced their stakes in IOVA. Franklin Resources Inc. purchased a new stake in Lion Biotechnologies in the 2nd quarter valued at about $37,844,000. FMR LLC purchased a new stake in Lion Biotechnologies in the 2nd quarter valued at about $20,833,000. Victory Capital Management Inc. purchased a new stake in Lion Biotechnologies in the 2nd quarter valued at about $19,013,000. Broadfin Capital LLC purchased a new stake in Lion Biotechnologies in the 2nd quarter valued at about $16,731,000. Finally, Vanguard Group Inc. purchased a new stake in Lion Biotechnologies in the 2nd quarter valued at about $16,113,000. 66.57% of the stock is owned by institutional investors.

About Lion Biotechnologies

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Lion Biotechnologies (NASDAQ:IOVA)

What are top analysts saying about Lion Biotechnologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Lion Biotechnologies Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit